Our findings could help to reduce arm morbidity in patients with IBC, as with newer systemic and dual anti-HER2 therapy many patients with IBC achieve nodal pCR.4 As the evidence is accumulating regarding the non-inferior oncological outcome of de-escalating ALND in non-IBC with nodal pCR post-NAC,14 identifying IBC with nodal pCR by evaluating the clipped node can possibly benefit those patients by avoiding ALND. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.